1. Home
  2. RENE vs MOLN Comparison

RENE vs MOLN Comparison

Compare RENE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RENE
  • MOLN
  • Stock Information
  • Founded
  • RENE 2021
  • MOLN 2004
  • Country
  • RENE United States
  • MOLN Switzerland
  • Employees
  • RENE N/A
  • MOLN N/A
  • Industry
  • RENE Blank Checks
  • MOLN
  • Sector
  • RENE Finance
  • MOLN
  • Exchange
  • RENE Nasdaq
  • MOLN Nasdaq
  • Market Cap
  • RENE 151.4M
  • MOLN 195.4M
  • IPO Year
  • RENE 2022
  • MOLN 2021
  • Fundamental
  • Price
  • RENE $11.66
  • MOLN $5.31
  • Analyst Decision
  • RENE
  • MOLN
  • Analyst Count
  • RENE 0
  • MOLN 0
  • Target Price
  • RENE N/A
  • MOLN N/A
  • AVG Volume (30 Days)
  • RENE 3.4K
  • MOLN 25.3K
  • Earning Date
  • RENE 01-01-0001
  • MOLN 08-26-2024
  • Dividend Yield
  • RENE N/A
  • MOLN N/A
  • EPS Growth
  • RENE 42.92
  • MOLN N/A
  • EPS
  • RENE 0.43
  • MOLN N/A
  • Revenue
  • RENE N/A
  • MOLN $7,105,397.00
  • Revenue This Year
  • RENE N/A
  • MOLN N/A
  • Revenue Next Year
  • RENE N/A
  • MOLN $29.41
  • P/E Ratio
  • RENE $26.90
  • MOLN N/A
  • Revenue Growth
  • RENE N/A
  • MOLN N/A
  • 52 Week Low
  • RENE $10.94
  • MOLN $3.32
  • 52 Week High
  • RENE $11.67
  • MOLN $12.70
  • Technical
  • Relative Strength Index (RSI)
  • RENE 70.34
  • MOLN 46.11
  • Support Level
  • RENE $11.64
  • MOLN $5.06
  • Resistance Level
  • RENE $11.65
  • MOLN $5.44
  • Average True Range (ATR)
  • RENE 0.00
  • MOLN 0.16
  • MACD
  • RENE -0.00
  • MOLN -0.03
  • Stochastic Oscillator
  • RENE 100.00
  • MOLN 26.88

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: